Jump to navigation Jump to search


WikiDoc Resources for Omegaven


Most recent articles on Omegaven

Most cited articles on Omegaven

Review articles on Omegaven

Articles on Omegaven in N Eng J Med, Lancet, BMJ


Powerpoint slides on Omegaven

Images of Omegaven

Photos of Omegaven

Podcasts & MP3s on Omegaven

Videos on Omegaven

Evidence Based Medicine

Cochrane Collaboration on Omegaven

Bandolier on Omegaven

TRIP on Omegaven

Clinical Trials

Ongoing Trials on Omegaven at Clinical

Trial results on Omegaven

Clinical Trials on Omegaven at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Omegaven

NICE Guidance on Omegaven


FDA on Omegaven

CDC on Omegaven


Books on Omegaven


Omegaven in the news

Be alerted to news on Omegaven

News trends on Omegaven


Blogs on Omegaven


Definitions of Omegaven

Patient Resources / Community

Patient resources on Omegaven

Discussion groups on Omegaven

Patient Handouts on Omegaven

Directions to Hospitals Treating Omegaven

Risk calculators and risk factors for Omegaven

Healthcare Provider Resources

Symptoms of Omegaven

Causes & Risk Factors for Omegaven

Diagnostic studies for Omegaven

Treatment of Omegaven

Continuing Medical Education (CME)

CME Programs on Omegaven


Omegaven en Espanol

Omegaven en Francais


Omegaven in the Marketplace

Patents on Omegaven

Experimental / Informatics

List of terms related to Omegaven

Omegaven is a fatty acid emulsion produced by Fresenius Kabi. It is used for total parenteral nutrition (feeding directly into a venous catheter), e.g. in short bowel syndrome. It is rich in omega-3 fatty acids.

It has gained popularity in children in preference to the more commonly used Intralipid after case reports that it reduced the risk of liver damage.[1]

A recent study indicated that the use of Omegaven may be an appropriate intervention strategy for newborns with a very low birth weight, gastrochisis, and jejunal atresia.[2]

It is currently undergoing a clinical trial at National Taiwan University Hospital.[3]

Although the use of Omegaven in children in the United States is experimental, the use of it in adults in Europe is less controversial.[4] In European studies, Omegaven has been associated with a reduction in psoriasis, when contrasted to administration of omega-6 fatty acid Lipoven.[5] Omegaven has also been associated with reduced mortality and antibiotic use during hospital stays.[6]


  1. Gura KM, Duggan CP, Collier SB; et al. (2006). "Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management". Pediatrics. 118 (1): e197–201. doi:10.1542/peds.2005-2662. PMID 16818533.
  2. Christensen RD, Henry E, Wiedmeier SE, Burnett J, Lambert DK (2007). "Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease". Journal of perinatology : official journal of the California Perinatal Association. 27 (5): 284–90. doi:10.1038/ PMID 17344923.
  3. Template:ClinicalTrials
  4. A Doctor's Push For Drug Pits Him Against Its Maker at Wall Street Journal
  5. Mayser P, Grimm H, Grimminger F (2002). "n-3 fatty acids in psoriasis". Br. J. Nutr. 87 Suppl 1: S77–82. PMID 11895157.
  6. Heller AR, Rössler S, Litz RJ; et al. (2006). "Omega-3 fatty acids improve the diagnosis-related clinical outcome". Crit. Care Med. 34 (4): 972–9. doi:10.1097/01.CCM.0000206309.83570.45. PMID 16484909.

External links

Template:WikiDoc Sources